|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that Asp-664 plays a critical role in the generation of Alzheimer-related pathophysiological and behavioral changes in human APP transgenic mice, possibly as a cleavage site or via protein-protein interactions.
|
16641106 |
2006 |
|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
A striking observation was that astrocytes associated with cerebral vessels laden with Aβ or associated with Aβ plaques showed increased reactivity in APP/PS1 mice lacking apoA-I.No behavioral changes were observed.
|
31084613 |
2019 |
|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Behavioral Changes and Hippocampus Glucose Metabolism in APP/PS1 Transgenic Mice via Electro-acupuncture at Governor Vessel Acupoints.
|
28174534 |
2017 |
|
Abnormal behavior
|
0.200 |
AlteredExpression
|
phenotype |
BEFREE |
Our results showed that the transplantation of PD-MSCs into Aβ1-42-infused mice significantly improved cognitive impairment, and behavioral changes attenuated the expression of APP, BACE1, and Aβ, as well as the activity of β-secretase and γ-secretase.
|
24336078 |
2013 |
|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormal behavior
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease.
|
20523046 |
2010 |
|
Abnormal behavior
|
0.200 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of Parkin in APP/PS1 transgenic mice restored activity-dependent synaptic plasticity and rescued behavioral abnormalities.
|
24105468 |
2014 |
|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
This study systematically characterized changes in behavioral abnormalities in APP/PS1 transgenic mice.
|
28191738 |
2017 |
|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Moreover, some behavioral disturbances displayed by APP mice lacking apoE are even more pronounced than those of APP mice expressing apoE.
|
10718322 |
2000 |
|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice.
|
16687508 |
2006 |
|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
These findings demonstrated that the behavioral abnormalities of the APP-PS1 mice started at about 30 weeks of age and that the hippocampus and temporal cortex were the most sensitive regions during early-stage AD.
|
20307581 |
2010 |
|
Abnormal behavior
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
These transgenic mice showed the same early behavioral disturbances and defects and increased premature death as the APP/London (APP V717I), APP/Swedish (K670N, M671L), and other APP transgenic mice described previously.
|
10671319 |
2000 |
|
Abnormal behavior
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
These studies provide solid evidence that EE is a useful intervention to ameliorate behavioral changes and AD pathology in HFD-induced aggravation of AD symptoms in APP transgenic mice.
|
22197104 |
2012 |
|
Abnormal behavior
|
0.200 |
AlteredExpression
|
phenotype |
BEFREE |
The hypoactivity and the spatial learning deficit were associated with higher cytochrome oxidase activity seen in thalamic nuclei, indicating that altered regional brain metabolism caused by betaAPP transgene expression may be responsible for the behavioral changes.
|
12559409 |
2002 |
|
Abnormal social behavior
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of vision
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acquired Immunodeficiency Syndrome
|
0.010 |
Biomarker
|
group |
BEFREE |
We conclude that damaged DNA and altered patterns of expression of DNA repair proteins and APP are common findings in the brains of AIDS patients at autopsy, but do not have a spatial relationship to HIV-infected macrophages.
|
11089573 |
2000 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease.
|
28448946 |
2017 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
pH-Dependent Cu(II) coordination to amyloid-β peptide: impact of sequence alterations, including the H6R and D7N familial mutations.
|
21980910 |
2011 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide.
|
15591071 |
2005 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease.
|
16651627 |
2006 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.
|
1671712 |
1991 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of the key molecules involved in chronic copper exposure-aggravated memory impairment in transgenic mice of Alzheimer's disease using proteomic analysis.
|
25352456 |
2015 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
APP/PS1 transgenic mice treated with aluminum: an update of Alzheimer's disease model.
|
22507317 |
2012 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease.
|
12746438 |
2003 |